Dominant Optic Atrophy and Leber’s Hereditary Optic Neuropathy: Update on Clinical Features and Current Therapeutic Approaches☆,☆☆
Introduction
Inherited optic neuropathies cause irreversible, bilateral visual loss that almost always presents in young patients, with an estimated prevalence of 1 in 10,000.1, 2 Leber hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA) are the two most common disorders of the inherited optic neuropathies seen in clinical practice.2 During the past 25 years, there has been significant progress in the understanding of the clinical, genetic, and pathophysiological basis of these disorders.3 Point mutations of mitochondrial DNA (mtDNA) cause LHON, whereas mutations in the nuclear optic atrophy 1 (OPA1) gene is responsible for most cases of DOA.1, 3, 4 Despite these different genetic bases, LHON and DOA have some overlapping clinical and pathological features, such as selective vulnerability of the retinal ganglion cell (RGC) layer and progressive visual loss due to the mitochondrial dysfunction.1, 2, 3, 5 Respiratory complex I dysfunction caused by mutations of mtDNA in LHON leads to increased production of reactive oxygen species (ROS) and possibly deficient ATP production. Abnormal mitochondrial metabolism caused by OPA1 mutations in DOA makes the RGCs vulnerable to apoptotic-induced degeneration.3, 5, 6 Both disorders have a common pathophysiological outcome that is the generation of excessive ROS cause by mitochondrial dysfunction, which acts as a signal for RGC apoptosis.3, 4, 5 The following discussion provides a review of the current state of understanding about the pathogenesis of these disorders. Our focus is on how emerging insights are leading to new therapeutic approaches, with special emphasis on the ongoing clinical trials for LHON and DOA.
Section snippets
Genetics
DOA is the most commonly diagnosed inherited optic neuropathy, with a prevalence of 1:12,000 to 1:50,000.3, 7, 8 The OPA1 gene is a nuclear gene on chromosome 3q28-q29, and the protein produced by the OPA1 gene is a dynamin-related GTPase, which is essential for mitochondrial inner membrane fusion and maintenance of mitochondrial cristae network.3, 11, 12, 13 The OPA1 protein also is associated with other functions in mitochondria, including interaction with the oxidative phosphorylation
Genetics
LHON is the second most common inherited optic neuropathy and the most common primary mtDNA disorder. LHON is a maternally inherited genetic disorder with an estimated prevalence of 1 in 35,000.1, 18, 35 Up to 90% of LHON cases are owing to 1 of the 3 “major” mtDNA point mutations: m.3460G > A (MTND1); m.11778G > A (MTND4); and m.14484T > C (MTND6). These mutations occur in the ND1, ND4, and ND6 genes of the mtDNA, respectively, and they all encode protein subunits of the metabolically
Treatments
Various vitamin supplements, especially vitamins E and C, and other compounds, including alpha-lipoic acid, l-carnitine, creatine, l-arginine, and cysteine, have been used alone or in combination in an attempt to treat blindness caused by mitochondrial optic neuropathies. However, there is limited evidence of the benefit for these approaches.2, 18, 52
More recently, clinical studies have been interpreted as providing evidence in support of the use of ubiquinone analogues.2, 18, 52 Ubiquinone is
Conclusions
Blindness can result from mutations involving mitochondrial genes, either at the level of the nucleus (the OPA1 gene) or at the level of the mitochondria, although the clinical profile for each differs. In the former, insidious bilateral visual loss occurs, where in the latter, acute or subacute, typically sequential blindness ensues. Both disorders, however, share the preferential involvement of the papillomacular bundle. No definitive and widely accepted treatment exists for either disorder,
References (74)
- et al.
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Prog Retinal Eye Res
(2011) - et al.
The neuro-ophthalmology of mitochondrial disease
Survey Ophthalmol
(2010) - et al.
Mitochondrial dysfunction as a cause of optic neuropathies
Prog Retinal Eye Res
(2004) - et al.
Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis
J Biol Chem
(2003) - et al.
OPA1-associated disorders: Phenotypes and pathophysiology
Int J Biochem Cell Biol
(2009) - et al.
Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis viaOPA1-dependent cristae remodeling
Cell
(2006) - et al.
Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy patients with mutations in the opa1 gene
J Neurol Sci
(2015) - et al.
The epidemiology of Leber hereditary optic neuropathy in the North East of England
Am J Hum Genet
(2003) - et al.
Respiratory complex 1 dysfunction due to mitochondrial DNA mutations shifts the voltage threshold for opening of the permeability transition pore toward resting levels
J Biol Chem
(2009) - et al.
Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations
Ophthalmology
(1996)
Retinal nerve fiber layer evaluation by optical coherence tomography in unaffected carriers with Leber’s hereditary optic neuropathy mutations
Ophthalmology
Bioenergetics shapes cellular death pathways in Leber’s hereditary optic neuropathy: A model of mitochondrial neurodegeneration
Biochim Biophys Acta
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone
Biochem Biophys Res Commun
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging
Bioorg Med Chem Lett
Initial experience in the treatment of inherited mitochondrial disease with EPI-743
Mol Genet Metab
Gene therapy for mitochondrial diseases: Leber hereditary optic neuropathy as the first candidate for a clinical trial
C R Biol
Gene therapy for Leber hereditary optic neuropathy: Initial results
Ophthalmology
Treatment strategies for inherited optic neuropathies: Past, present and future
Eye
Dominant optic atrophy: Updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation
Curr Opin Ophthalmol
Mitochondrial dysfunction in optic neuropathies: Animal models and therapeutic options
Curr Opin Neurol
Dominant optic atrophy
Orphanet J Rare Dis
Dominant optic atrophy: Novel OPA1 mutations and revised prevalence estimates
Ophthalmology
Autosomal dominant optic atrophy: Penetrance and expressivity in patients with OPA1 mutations
Am J Ophthalmol
Dominant optic atrophy in Denmark—Report of 15 novel mutations in OPA1, using a strategy with a detection rate of 90%
BMC Med Genet
Mutation spectrum and splicing variants in the OPA1 gene
Hum Genet
OPA1 requires mitofusin 1 to promote mitochondrial fusion
Proc Natl Acad Sci U S A
Dominant optic atrophy, OPA1, and mitochondrial quality control: Understanding mitochondrial network dynamics
Mol Neurodegener
Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy
Ann Neurol
OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion
Brain
Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 Novel OPA1Mutations
Human Mutation
Therapeutic approaches to inherited optic neuropathies
Semin Neurol
Infantile optic atrophy with dominant mode of inheritance: A clinical and genetic study of 19 Danish families
Acta Ophthalmol Suppl
Hereditary optic neuropathies
The prevalence and natural history of dominant optic atrophy due to OPA1 mutations
Ophthalmology
Early macular retinal ganglion cell loss in dominant optic atrophy: Genotype-phenotype correlation
Am J Ophthalmol
Autosomal dominant hereditary optic neuropathy (ADOA): A review of the genetics and clinical manifestations of ADOA and ADOA+
Semin Ophthalmol
Mitochondrial DNA defects and selective extraocular muscle involvement in CPEO
Invest Ophthalmol Vis Sci
Cited by (50)
Permanent transduction of retinal ganglion cells by rAAV2-retro
2024, Experimental Eye ResearchApplication of super-resolution microscopy in mitochondria-dynamic diseases
2023, Advanced Drug Delivery ReviewsFundus imaging of retinal ganglion cells transduced by retrograde transport of rAAV2-retro
2022, Experimental Eye ResearchCitation Excerpt :Adeno-associated virus (AAV) holds promise for gene therapy in conditions such as Leber's hereditary optic neuropathy, a degenerative disease of retinal ganglion cells caused by a mutation in mitochondrial DNA (Chun and Rizzo, 2017; Gilhooley et al., 2021; Guy et al., 2014; Koilkonda et al., 2014).
A differential loss of nerve fiber layer thickness and retinal ganglion cell complex in toxic and nutritional optic neuropathy
2021, Advances in Ophthalmology Practice and ResearchRole of inner mitochondrial protein OPA1 in mitochondrial dysfunction by tobacco smoking and in the pathogenesis of COPD
2021, Redox BiologyCitation Excerpt :Nonetheless, there are reports which show non-toxic stress response due to CSE induces mitochondrial elongation and also discusses the contrast/varied observation based on different cell types used in the study [41]. Apart from lung diseases, the most common inherited and observed optic neuropathies Dominant optic atrophy (DOA) and Leber hereditary optic neuropathy (LHON) are linked to the mutations in the mitochondrial related genes [42]. Among them, the DOA is associated with the mutations in the OPA1 and its isoforms [43].
- ☆
Research on DOA in Korea (BYC) was supported by Biomedical Research Institute grant, Kyungpook National University Hospital (2013).
- ☆☆
J.F.R. is on the data safety monitoring committee for GenSight.